BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $237,463 | -12.5% | 33,540 | -13.0% | 0.02% | -13.6% |
| Q2 2023 | $271,322 | -18.5% | 38,540 | -3.5% | 0.02% | -21.4% |
| Q1 2023 | $333,100 | +72788.4% | 39,940 | +0.4% | 0.03% | -33.3% |
| Q4 2022 | $457 | -99.9% | 39,800 | +1.9% | 0.04% | -17.6% |
| Q3 2022 | $492,000 | +4.7% | 39,050 | -12.1% | 0.05% | +21.4% |
| Q2 2022 | $470,000 | -26.8% | 44,450 | +12.5% | 0.04% | -19.2% |
| Q1 2022 | $642,000 | +2.7% | 39,500 | -12.5% | 0.05% | +2.0% |
| Q4 2021 | $625,000 | +4.9% | 45,125 | +8.8% | 0.05% | -16.4% |
| Q3 2021 | $596,000 | +44.0% | 41,475 | +58.3% | 0.06% | +45.2% |
| Q2 2021 | $414,000 | +123.8% | 26,200 | +44.0% | 0.04% | +121.1% |
| Q1 2021 | $185,000 | – | 18,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |